Our focus on differentiated ASO technology, powered by Alloy Therapeutics’ Genetic Medicines platform and novel AntiClastic™ ASO format, paves the way for a unique and rapid path to meaningful ocular solutions for patients.
Uses established building blocks that make clinical and market-validated ASOs.
Leverages proprietary structures to improve potency and promote the delivery of antisense to target RNA, and optimizes engagement of RNaseH for precise excision.
Minimizes off-target interactions with unintended RNA targets , mitigates the inflammatory response—potentially improving the therapeutic index.
Aldebaran utilizes ocular disease genetics to identify targets for well-defined patient populations with broad therapeutic potential. We are passionate about finding solutions for:
We are advancing a diversified portfolio of precision ocular AntiClastic ASOs for patients with severe blinding diseases. We are using human iPSC and in vivo models to de-risk and accelerate therapeutics to the clinic.
We have assembled a world-class group of company builders, scientists, and leaders at the forefront of ocular research and development and ASO therapeutics.
Founder, CEO, Board Director
Co-Founder, SAB Member
Board Director, Alloy Head of Genetic Medicines
CEO, Founder of Alloy Therapeutics
82VS, the venture studio of Alloy Therapeutics, helps efficiently launch new multi-asset startup companies by leveraging the capabilities of the Alloy ecosystem at large.
© 2023. All rights reserved.